Our history
Polpharma Biologics as an entity is a relatively new and innovative company, however it has nearly a century of history through having formerly been part of Polpharma.
We now operate in three international sites including one of the most advanced biologics manufacturing sites in Europe located near Warsaw in Poland.
Polpharma Biologics Growth Timeline
1935
Polpharma established.
2000
Acquisition of Polpharma by Jerzy Starak , a committed and visionary entrepreneur who still controls Polpharma and Polpharma Biologics today.
2010
Polpharma, a leading pharmaceutical company in Poland and the central European region, launches biotech operations.
2013
Biotechnology R&D centre established in Gdańsk.
2014
Bioeq established – joint venture with Atos on the co-development of Ranibizumab.
2016
Acquisition of Bioceros BV, an early stage biotech development company in Utrecht, the Netherlands.
2018
Rapid development of the biotechnology R&D centre in Gdańsk.
2019
Creation of an independent Polpharma Biologics (spin-off from Polpharma). Out-licensing deal for Natalizumab with Sandoz. Out-licensing deal for Ranibizumab with Coherus.
2020
Duchnice manufacturing and development site joins Polpharma Biologics.
2021
2021 Bioeq, a joint venture of Polpharma Biologics Group, enters into an agreement with Teva to commercialize a biosimilar drug to Ranibizumab in Europe and Canada